WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New search    Hide text from Guidelines

C CARDIOVASCULAR SYSTEM

This group comprises substances used for the treatment of cardiovascular conditions.
Drugs used for the treatment of hypertension are classified in C02 - Antihypertensives, C03 - Diuretics, C07 - Beta blocking agents, C08 - Calcium channel blockers, and C09 - Agents acting on the renin-angiotensin system. For the classification of combination products of antihypertensives from different ATC groups, the following ranking should be used, from higher to lower precedence: C09, C07, C08, and C03.


C10 LIPID MODIFYING AGENTS

The DDDs are based on the treatment of hypercholesterolemia.


C10A LIPID MODIFYING AGENTS, PLAIN

Pantethine, which is also used in the treatment of hyperlipidemi, is classified as a vitamin in A11HA.


C10AA HMG CoA reductase inhibitors

This group comprises agents which act as competitive inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG CoA reductase).
Atorvastatin in combination with amlodipine is classified in C10BX03.

C10AB Fibrates

Clofibrate and analogues are classified here.

The DDD for fenofibrate is based on the micronised formulation.

C10AC Bile acid sequestrants

This group comprises substances (such as colestyramine and colestipol) which reduces the cholesterol level by increasing the excretion of bile acid.

C10AD Nicotinic acid and derivatives

This group comprises high strength preparations (e.g. nicotinic acid tab 500 mg) used as cholesterol reducers. Nicotinic acid or derivatives in low strength preparations (e.g. nicotinic acid tab 50 mg) are classified in C04A - Peripheral vasodilators.
Combinations of nicotinic acid and laropiprant are classified in C10AD52.

C10AX Other lipid modifying agents

This group comprises all cholesterol and triglyceride reducers, which cannot be classified in the preceding groups.
Icosapent ethyl is classified in C10AX06 - omega-3-triglycerides incl. other esters and acids.
Sulodexide is classified in B01AB.

The DDD for evolocumab is based on dosing every second week.
The DDD for volanesorsen is based on the treatment of familial chylomicronemia syndrome.

Last updated: 2024-01-26